Matthew During, M.D., Ph.D. to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics
April 26 2021 - 7:30AM
Business Wire
Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX)
("Brooklyn"), a biopharmaceutical company focused on exploring the
role that cytokine-based therapy can have in treating patients with
cancer, today announced the appointment of Matthew During, M.D.,
Ph.D. to the Company’s Scientific Advisory Board, effective April
26, 2021.
Dr. During is a Harvard, MIT and Yale trained neuroscientist. He
has served for 9 years as a member of the faculty of Yale as
Professor of Neurosurgery, and as a Professor at Thomas Jefferson,
Cornell, and Ohio State Universities. Dr. During was a pioneer in
the use of viral vectors for neurological disorders, and was the
first to carry out gene transfer into the brain of a human child.
Dr. During was the Principal Investigator and the FDA sponsor for
two pioneering gene therapy studies on neurodevelopmental and
movement disorders and has published over 250 scientific articles,
with many in the world’s most prestigious journals including
Nature, Science, Cell, Nature Medicine, Nature Genetics, the Lancet
and Science Translational Medicine. Dr. During was a co-founder of
Merlin Pharmaceuticals, Neurologix, Vector Neurosciences, Emrys
Bio, Nightstar Therapeutics, and founder of Ovid Therapeutics where
he previously served as President, Chief Scientific Officer and
chair of the Scientific Advisory Board.
“Dr. During brings a depth of experience to the Scientific
Advisory Board of Brooklyn ImmunoTherapeutics which will be
important as we develop IRX-2 and explore opportunities to license
leading edge gene editing and cell therapy technologies,” said
Howard J. Federoff, M.D., Ph.D., Brooklyn ImmunoTherapeutics’ Chief
Executive Officer. “Dr. During has been a leader in drug
development, particularly in the field of gene and cell therapies.
He has a demonstrated ability to advance ground-breaking science
into clinical advances that have the potential to change the way
diseases are treated.”
“Brooklyn ImmunoTherapeutics is well-positioned to be a key
player in the cancer field with IRX-2, its clinical stage
cytokine-based therapy that is currently being evaluated both as a
single agent and in combination with other anti-cancer agents in a
number of solid tumor indications,” said Dr. During. “In addition,
I’m excited by the opportunity for Brooklyn to license leading edge
gene editing technology that may provide an opportunity to develop
a multitude of drugs for serious conditions including cancer and
blood disorders. I look forward to working with the team at
Brooklyn ImmunoTherapeutics at such an important time in its
development.”
About Brooklyn ImmunoTherapeutics
Brooklyn is focused on exploring the role that cytokine-based
therapy can have in treating patients with cancer, both as a single
agent and in combination with other anti-cancer therapies. The
company is also exploring opportunities to advance therapies using
leading edge gene editing/cell therapy technology through its
option agreement with Factor Bioscience/Novellus.
Brooklyn’s most advanced program is studying the safety and
efficacy of IRX-2 in patients with head and neck cancer. In a Phase
2A clinical trial in head and neck cancer, IRX-2 demonstrated an
overall survival benefit. Additional studies are either underway or
planned in other solid tumor cancer indications.
For more information about Brooklyn and its clinical programs,
please visit www.BrooklynITx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210426005217/en/
Media Contact MacDougall Nicholas Chang 781-235-3060
nchang@macbiocom.com
IR Contact CORE IR 516-222-2560
investors@brooklynitx.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Sep 2023 to Sep 2024